Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Disruption of TRIO signaling through PDE4A5 in neurodevelopmental disorders

Award Number: F31MH127891
ORGANIZATION: NATIONAL INSTITUTE OF MENTAL HEALTH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 09/01/2021
PERIOD OF PERFORMANCE END DATE: 07/31/2023

Group Awards By:

View Award Description

Disruption of TRIO signaling through PDE4A5 in neurodevelopmental disorders - Project Summary Schizophrenia (SCZ) and autism (ASD) are highly debilitating neurodevelopmental disorders that affect millions of people. An allelic series of heterozygous loss-of-function (LOF) or damaging variants spread throughout the entire TRIO gene are significantly enriched in individuals with SCZ and ASD, suggesting that reduced TRIO function causes pathology. Indeed, our lab has shown that deletion of a single TRIO allele in mouse cortical excitatory neurons (in NEX-TRIO+/– mice) yields diverse behavioral deficits and severe defects in dendritic structure and synaptic activity. TRIO acts downstream of cell surface receptors to control axon and dendrite pathfinding, and synapse development. However, the signaling mechanisms compromised by TRIO variants and how defects in these processes disrupt neuronal development remain completely unclear. Our lab identified PDE4A5 as a new candidate TRIO signaling partner due to its reduced levels in TRIO-deficient mouse cortex and its ability to co-immunoprecipitate with TRIO. My proposal will test the hypothesis that TRIO interacts functionally with PDE4A5 to regulate neuron development and function in two complementary aims. My first aim is to determine how TRIO and PDE4A5 interact functionally and how these functions are impacted by disease-associated variants. PDE4A5 coimmunoprecipitates with TRIO, but how these proteins interact and how these interactions impact each protein’s function is poorly understood. I will use purified recombinant proteins to perform quantitative binding assays and determine whether PDE4A5 and TRIO interact directly and define the minimal TRIO and PDE4A5 fragments sufficient to mediate interaction. I will engineer disorder-associated variants that lie within the TRIO:PDE4A5 interaction interface to determine whether and how these variants impact the Trio:PDE4A5 interaction. I will use my purified proteins and an arsenal of in vitro and cell-based assays to measure how interactions between the TRIO and PDE4A5 impact their catalytic activities. My second aim is to determine how TRIO:PDE4A5 interactions regulate neuronal development. Disruption of a single TRIO allele in cultured cortical neurons yields defects in dendrite and dendritic spine development similar to those observed in vivo. How disruption of TRIO:PDE4A5 interactions contributes to the pathophysiology seen in TRIO deficient neurons is unclear. I will use shRNA-mediated knockdown of PDE4A5 to determine whether PDE4A5 is necessary for dendrite and dendritic spine development. I will perform knockdown/complementation and confocal microscopy in cultured cortical neurons to determine whether and how disruptions in TRIO:PDE4A5 interaction affects PDE4A45 localization and neuron development. I will use a small-molecule PDE4A5 activator to test whether pharmacological manipulation of PDE4A5 can rescue deficits in development of TRIO+/– and TRIO–/– cortical neurons in culture and in NEX-TRIO+/– and NEX-TRIO-/– mice.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$17,246 )
2024	2022	YALE UNIV	150 MUNSON ST	NEW HAVEN	CT	06511	SOUTH CENTRAL CT	USA	Mental Health Research Grants	001	2	5/22/2024	NON-COMPETING CONTINUATION	-$15,050
2024	2022	YALE UNIVERSITY	105 WALL ST	NEW HAVEN	CT	06511	SOUTH CENTRAL CT	USA	Mental Health Research Grants	000	2	10/26/2023	NON-COMPETING CONTINUATION	-$2,196
														Subtotal = -$17,246

Issue Date FY: 2022 ( Subtotal = $46,752 )
2022	2022	YALE UNIVERSITY	105 WALL ST	NEW HAVEN	CT	06511	SOUTH CENTRAL CT	USA	Mental Health Research Grants	000	2	8/12/2022	NON-COMPETING CONTINUATION	$46,752
														Subtotal = $46,752

Issue Date FY: 2021 ( Subtotal = $46,036 )
2021	2021	YALE UNIVERSITY	105 WALL ST	NEW HAVEN	CT	06511	SOUTH CENTRAL CT	USA	Mental Health Research Grants	001	1	6/11/2021	NEW	$0
2021	2021	YALE UNIVERSITY	105 WALL ST	NEW HAVEN	CT	06511	SOUTH CENTRAL CT	USA	Mental Health Research Grants	000	1	6/11/2021	NEW	$46,036
														Subtotal = $46,036

Grand Total All Awards = $75,542

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Disruption of TRIO signaling through PDE4A5 in neurodevelopmental disorders

Award Number: F31MH127891

ORGANIZATION: NATIONAL INSTITUTE OF MENTAL HEALTH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 09/01/2021

PERIOD OF PERFORMANCE END DATE: 07/31/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer